Leerapun Apinya, Thaikruea Lakkana, Pisespongsa Pises, Chitapanarux Taned, Praisontarangkul Ong-Ard, Thongsawat Satawat
Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
J Med Assoc Thai. 2013 May;96(5):531-7.
Primary liver cancer included hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), is the leading cancer with high mortality in Thailand. We aim to evaluate the overall survival and predictor of mortality in patients with HCC and CCA.
We reviewed medical records of 786 patients with liver mass between July 2007 and June 2010, 287 patients were HCC and 449 patients were CCA. The overall survival and prognostic variables for survival were analyzed.
The mean age of HCC patients and CCA patient were 53.8 years and 59.2 years. Male was predominant, 85% and 74% in HCC and CCA. By BCLC staging for HCC, patients at early stage (A), intermediate stage (B), advanced stage (C), and terminal stage (D) were 40 (13.9%), 105 (36.6%), 95 (33.1%), and 43 (15.0%). Among 449 CCA patients, 143 (31.8%) were intrahepatic type and 306 (68.2%) were ductal type. The mean follow-up time for HCC and CCA patients were 20.1 and 16.7 months. The 1-year, 2-year, and 3-year survival of HCC and CCA were 55%, 34%, 31.3% and 54%, 21.2%, 19.1%, respectively. Predictor of death in HCC patients included portal vein thrombosis and did not receive any treatment (p < 0.05). Meanwhile, the predictor of death in CCA patient included intrahepatic type, total bilirubin > 2 mg/dl, CA 19-9 > 100, and unresectable tumor (p< 0.05).
The survival of patients who received any type of treatment was much better than in the past. Still, in patients with advanced disease whom only supportive treatments were provided, the prognosis is grave.
原发性肝癌包括肝细胞癌(HCC)和胆管癌(CCA),是泰国死亡率很高的主要癌症。我们旨在评估HCC和CCA患者的总生存期及死亡预测因素。
我们回顾了2007年7月至2010年6月期间786例肝脏肿物患者的病历,其中287例为HCC患者,449例为CCA患者。分析了总生存期及生存的预后变量。
HCC患者和CCA患者的平均年龄分别为53.8岁和59.2岁。男性占主导,在HCC和CCA患者中分别占85%和74%。根据HCC的BCLC分期,早期(A期)、中期(B期)、晚期(C期)和终末期(D期)患者分别为40例(13.9%)、105例(36.6%)、95例(33.1%)和43例(15.0%)。在449例CCA患者中,143例(31.8%)为肝内型,306例(68.2%)为胆管型。HCC和CCA患者的平均随访时间分别为20.1个月和16.7个月。HCC和CCA的1年、2年和3年生存率分别为55%、34%、31.3%和54%、21.2%、19.1%。HCC患者的死亡预测因素包括门静脉血栓形成且未接受任何治疗(p<0.05)。同时,CCA患者的死亡预测因素包括肝内型、总胆红素>2mg/dl、CA 19-9>100和不可切除肿瘤(p<0.05)。
接受任何类型治疗的患者的生存期比过去要好得多。然而,对于仅接受支持性治疗的晚期疾病患者,预后仍然很差。